• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Xvivo Perfusion

261.00 SEK

+2.35 %

Less than 1K followers

XVIVO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.35 %
-2.54 %
+8.66 %
+39.87 %
+39.87 %
-9.12 %
-14.00 %
-29.08 %
+1,273.68 %

Xvivo Perfusion operates in the medical technology industry and focuses on the development and manufacturing of systems for organ transplantation and perfusion. Examples of products that the company supplies include cannulas, organ storage and cooling solutions. The company's products are aimed at healthcare institutions and surgeons. Xvivo Perfusion operates globally, was founded in 1998 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
8.22B SEK
Turnover
14.91M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.7.
2026

Interim report Q2'26

22.10.
2026

Interim report Q3'26

27.1.
2027

Annual report '26

Press release26.06.2026 klo 16.00

Conference call on Interim Report April-June 2026

Xvivo Perfusion
Xvivo, Audiocast, Q2'26
Webcast14.07.2026 klo 15.00

Xvivo, Audiocast, Q2'26

Xvivo Perfusion
Press release18.05.2026 klo 14.45

Regulatory derogation and reimbursement in France enable life-saving use of XVIVO’s heart technology

Xvivo Perfusion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release27.04.2026 klo 19.22

Redeye: Xvivo Perfusion (Q1 Review): A strong start to an eventful year

Xvivo Perfusion
Regulatory press release27.04.2026 klo 16.17

Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)

Xvivo Perfusion
Xvivo, Audiocast, Q1'26
Webcast24.04.2026 klo 15.00

Xvivo, Audiocast, Q1'26

Xvivo Perfusion
Regulatory press release24.04.2026 klo 08.30

Interim Report January – March 2026

Xvivo Perfusion
Press release22.04.2026 klo 22.50

XVIVO presents encouraging results from first clinical trial using hypothermic oxygenated perfusion (HOPE) in direct procurement DCD heart transplantation

Xvivo Perfusion
Regulatory press release22.04.2026 klo 22.24

Preliminary one-year follow-up data from the US PRESERVE trial for XVIVO’s heart technology presented at ISHLT in Toronto

Xvivo Perfusion
Press release21.04.2026 klo 15.30

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q1 2026

Xvivo Perfusion
Press release17.04.2026 klo 14.45

Conference call on Interim Report January-March 2026

Xvivo Perfusion
Press release16.04.2026 klo 15.00

The 12-month follow-up results from XVIVO’s European multicenter heart trial is now published in the European Heart Journal

Xvivo Perfusion
Regulatory press release01.04.2026 klo 14.00

Annual report 2025

Xvivo Perfusion
Regulatory press release19.03.2026 klo 13.30

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)

Xvivo Perfusion
Regulatory press release20.02.2026 klo 15.24

Correction: The Nomination Committee’s proposal for new board members

Xvivo Perfusion
Regulatory press release20.02.2026 klo 15.00

The Nomination Committee of XVIVO Perfusion AB (publ) proposes Emil Billbäck and Anne-Karen Hunt as new members of the Board of Directors

Xvivo Perfusion
Regulatory press release19.02.2026 klo 17.45

Management change at XVIVO – CFO transitions to new role

Xvivo Perfusion
Press release10.02.2026 klo 16.00

Change of date for publication of the Interim report January-March 2026

Xvivo Perfusion
Press release28.01.2026 klo 12.06

Redeye: XVIVO (Q4 interview) - Redeye talks with CEO Christoffer Rosenblad

Xvivo Perfusion
Press release28.01.2026 klo 11.03

Redeye: Xvivo Perfusion (Q4 Review) - Setting up for a strong 2026

Xvivo Perfusion